Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients
A Randomized, Controlled Study of Ibandronate for the Prevention of Bone Loss in Patients Who Have Received Allogeneic Bone Marrow Transplantation for Hematological Malignancies
Sponsor: M.D. Anderson Cancer Center
Listed as NCT00824993, this PHASE3 trial focuses on Hematological Malignancies and remains completed. Sponsored by M.D. Anderson Cancer Center, it has been updated 9 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Oct 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jul 2018 — Oct 2018 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE3
-
May 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Dec 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- M.D. Anderson Cancer Center
- Roche Pharma AG
For direct contact, visit the study record on ClinicalTrials.gov .